Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
357 participants
INTERVENTIONAL
2012-12-31
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea
NCT02131636
Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea
NCT01579084
Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris
NCT02218034
Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
NCT01659853
Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea
NCT03380390
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AGN-199201 Dose A Once Daily
AGN-199201 Dose A applied once daily to the face for 28 days.
AGN-199201 Dose A
AGN-199201 Dose A applied once or twice daily to the face for 28 days.
AGN-199201 Dose B Once Daily
AGN-199201 Dose B applied once daily to the face for 28 days.
AGN-199201 Dose B
AGN-199201 Dose B applied once or twice daily to the face for 28 days.
AGN-199201 Dose C Once Daily
AGN-199201 Dose C applied once daily to the face for 28 days.
AGN-199201 Dose C
AGN-199201 Dose C applied once or twice daily to the face for 28 days.
AGN-199201 Vehicle Once Daily
AGN-199201 Vehicle applied once daily to the face for 28 days.
AGN-199201 Vehicle
AGN-199201 Vehicle applied once or twice daily to the face for 28 days.
AGN-199201 Dose A Twice Daily
AGN-199201 Dose A applied twice daily to the face for 28 days.
AGN-199201 Dose A
AGN-199201 Dose A applied once or twice daily to the face for 28 days.
AGN-199201 Dose B Twice Daily
AGN-199201 Dose B applied twice daily to the face for 28 days.
AGN-199201 Dose B
AGN-199201 Dose B applied once or twice daily to the face for 28 days.
AGN-199201 Dose C Twice Daily
AGN-199201 Dose C applied twice daily to the face for 28 days.
AGN-199201 Dose C
AGN-199201 Dose C applied once or twice daily to the face for 28 days.
AGN-199201 Vehicle Twice Daily
AGN-199201 Vehicle applied twice daily to the face for 28 days.
AGN-199201 Vehicle
AGN-199201 Vehicle applied once or twice daily to the face for 28 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AGN-199201 Dose A
AGN-199201 Dose A applied once or twice daily to the face for 28 days.
AGN-199201 Dose B
AGN-199201 Dose B applied once or twice daily to the face for 28 days.
AGN-199201 Dose C
AGN-199201 Dose C applied once or twice daily to the face for 28 days.
AGN-199201 Vehicle
AGN-199201 Vehicle applied once or twice daily to the face for 28 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Laser light-source or other energy based therapy in the last 6 months
* Any prescription or over the counter product for the treatment of acne or rosacea in the last 14 days
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Allergan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Austin, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
199201-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.